Welcome to our dedicated page for Axcelis Tech Ord news (Ticker: ACLS), a resource for investors and traders seeking the latest updates and insights on Axcelis Tech Ord stock.
Axcelis Technologies reports developments tied to its role as a supplier of ion implantation systems and process applications for semiconductor manufacturing. Company updates commonly cover quarterly results, demand trends across memory, power, compound semiconductor and mature-node markets, and the performance of its customer support and installed-base services business.
News also includes technical participation at semiconductor industry conferences, lifecycle support for Purion-based implant platforms, sustainability targets for greenhouse gas emissions, investor-conference activity and governance changes such as finance leadership transitions. The recurring business context centers on equipment used in integrated-circuit fabrication and aftermarket services including spare parts, upgrades, maintenance and training.
On March 8, 2021, Axcelis Technologies (Nasdaq: ACLS) announced the shipment of its first Purion H200 SiC Power Series™ implanter. This advanced equipment, designed for silicon carbide applications, was sent to a key power device manufacturer to support production ramp-up. The Purion H200 is the only single wafer high current implanter tailored for high dose implant applications. CEO Mary Puma highlighted the growing market for power devices, which represented over 17% of 2020 system sales, signaling significant revenue potential for Axcelis.
Axcelis Technologies (Nasdaq: ACLS) has announced its participation in two upcoming virtual investor conferences. The first is the Susquehanna Financial Group Tenth Annual Technology Conference on March 9, 2021, where management will engage in virtual one-on-ones and small group meetings. The second is the B. Riley Inaugural Clean Tech and Sustainability Virtual Investor Conference on March 10, 2021, featuring a fireside chat at 10:30 am EST with subsequent one-on-one meetings. A replay of the latter event will be available afterward.
Axcelis Technologies (Nasdaq: ACLS) announced the shipment of its second Purion XEmax high energy evaluation system to a leading foundry in the Asia Pacific region, aimed at CMOS image sensor manufacturing. This shipment, part of the first quarter, aligns with Axcelis' goal of reaching a $650M target business model amid increasing demand for high energy implants in the image sensor market. The Purion XEmax features enhanced capabilities, including patented Boost Technology™ for precise control, and builds on the established Purion XE platform for improved photodiode performance.
Axcelis Technologies (ACLS) reported strong financial results for Q4 and full year 2020. Q4 revenue reached $122.2 million, up from $110.4 million in Q3. Net income rose to $14.7 million or $0.43 per diluted share, benefiting from a $0.11 tax benefit. For the year, revenue surged to $474.6 million, a 38% increase from 2019, with net income of $50.0 million and diluted EPS of $1.46. Looking ahead, Q1 2021 revenue is expected between $118 million and $138 million.
Axcelis Technologies (Nasdaq: ACLS) has announced the shipment of its Purion H200™ high current implanter to a second leading power device manufacturer. This shipment aims to support production ramp for silicon power devices and reflects Axcelis's growth strategy in the power device market. The Purion H200 is notable for its versatility, precision, and productivity, catering to a wide energy range from 5keV to 200keV. This system is designed to meet the unique needs of foundry and power device manufacturers, enhancing their ability to develop advanced material modification applications.
Axcelis Technologies (Nasdaq: ACLS), a key player in ion implantation solutions for the semiconductor industry, will participate in B. Riley Securities' Vision Day on January 28, 2021. The event features a fireside chat with Kevin Brewer, executive vice president and CFO, and Doug Lawson, executive vice president of corporate marketing and strategy, scheduled for 3:30 p.m. EST. A webcast replay will be available post-event. Founded over 40 years ago, Axcelis is dedicated to enhancing semiconductor manufacturing processes. For more information, visit www.axcelis.com.
Axcelis Technologies (Nasdaq: ACLS) updated its fourth quarter 2020 financial guidance, expecting revenue of approximately $120 million, exceeding previous guidance of $110 million. Gross margin is projected at 43%, improved from 41%, with earnings per share rising to $0.32 from $0.21. The company also announced a $100 million share repurchase program for 2021, indicating strong confidence in operational prospects. Upcoming financial results will be disclosed on February 10, 2021, with a conference call scheduled for February 11, 2021.
Axcelis Technologies (Nasdaq: ACLS) announced its participation in the 23rd Annual Needham Virtual Growth Conference from January 11-15, 2021. Key executives including President and CEO Mary Puma, CFO Kevin Brewer, and EVP Doug Lawson will engage in a fireside chat on January 13 at 11:30 a.m. EST. The event will include one-on-one meetings and a live webcast accessible on their website. Axcelis, based in Beverly, Mass., specializes in ion implantation solutions for the semiconductor industry, boasting over 40 years of experience.
Axcelis Technologies (Nasdaq: ACLS) will participate in the 12th Annual CEO Investor Summit on December 16, 2020. Key executives, including Mary Puma, Kevin Brewer, and Doug Lawson, will engage in a virtual format with investors and analysts. This event allows for up to six meetings per company, and a pre-recorded company overview will be available for viewing 24 hours prior. Registration is required by December 10, 2020 to ensure participation in this exclusive event.
Axcelis Technologies (NASDAQ: ACLS) will participate in the virtual D.A. Davidson Semicap, Laser and Optical Conference on December 15, 2020. The management team will hold one-on-one meetings throughout the event. With over 40 years of experience, Axcelis supplies innovative ion implantation solutions critical to the semiconductor industry's manufacturing process.